Investor Relations

Press Releases

 
Press Releases
  Date Title View
Aug 29, 2014
SILVER SPRING, Md., Aug. 29, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. District Court for the District of New Jersey has ruled in its favor in the company's case against Sandoz, Inc. regarding United Therapeutics' Remodulin® product.  In his opinion, Judge Peter Sheridan ruled that U.S. P...
Jul 29, 2014
SILVER SPRING, Md., July 29, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2014. "Our continued growth shows that our medicines are reaching increasing numbers of patients suffering from pulmonary arterial hypertension (PAH)," said Martine Rothb...
Jul 22, 2014
SILVER SPRING, Md., July 22, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its second quarter 2014 financial results before market open on Tuesday, July 29, 2014. United Therapeutics will host a half-hour teleconference on Tuesday, July 29, 2014, at 9:00 a.m. Eastern Time.  The telec...
Jun 27, 2014
SILVER SPRING, Md., June 27, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $500 million of the company's common stock.  This program will become effective on August 1, 2014, and will remain open for up to one year.  Purchases may be ma...
May 6, 2014
LA JOLLA, Calif. and SILVER SPRING, Md., May 6, 2014 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), today announced they have entered into a mult...
Apr 29, 2014
SILVER SPRING, Md., April 29, 2014 /PRNewswire/ -- Revenues of $289.4 million Net income of $137.5 million Earnings per Share of $2.73 per Basic Share or $2.43 per Diluted Share Non-GAAP Earnings of $1.77 per Basic Share or $1.57 per Diluted Share United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial...
Apr 22, 2014
SILVER SPRING, Md., April 22, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2014 financial results before market open on Tuesday, April 29, 2014. United Therapeutics will host a half-hour teleconference on Tuesday, April 29, 2014, at 9:00 a.m. Eastern Time.  The tel...
Mar 26, 2014
SILVER SPRING, Md., March 26, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin® (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration.  Remodulin ...
Feb 25, 2014
Silver Spring, MD, February 25, 2014: United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2013. "United Therapeutics continued to deliver strong results in 2013, reflecting growing demand for our Remodulin®, Tyvaso® and Adcirca® products," remarked Martin...
Feb 18, 2014
SILVER SPRING, Md., Feb. 18, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2013 financial results before market open on Tuesday, February 25, 2014. United Therapeutics will host a half-hour teleconference on Tuesday, February 25, 2014, at 9:00 a.m. Easte...
1
... NextLast
= add release to Briefcase